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Abstract
Aims: We previously demonstrated Proline rich tyrosine kinase 2 (Pyk2) plays important roles in regulating tumor
progression, migration and invasion in hepatocellular carcinoma (HCC). In this study, we aimed to examine the role of
proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in HCC and to explore its underlying molecular mechanism.
Methodology/Principal Findings: Stable transfectants either overexpressing or suppressing Pyk2 were established in
different HCC cell lines. MTT, colony formation and Annexin-V assays were employed to examine their in vitro responses to
cisplatin. Xenograft ectopic and orthotopic nude mice models were generated to investigate the in vivo responses of them
to cisplatin treatment. cDNA microarray was performed to identify Pyk2-induced genes which were further validated by
quantitative real-time RT-PCR using clinical HCC samples. In vitro functional study demonstrated that Pyk2-overexpressing
HCC transfectants exhibited relatively lower cytotoxicity, higher colony-forming ability and lower apoptosis to cisplatin
compared with the control transfectants. Moreover, Pyk2 overexpressing HCC transfectants had a higher survival rate under
cisplatin treatment by up-regulation of AKT phosphorylation. In vivo xenograft nude mice model demonstrated that Pyk2-
overexpressing transfectants developed higher tolerance to cisplatin treatment together with less tumor necrosis and
apoptosis. cDNA microarray analysis revealed that there were more than 4,000 genes differentially expressed upon
overexpression of Pyk2. Several upregulated genes were found to be involved in drug resistance and invasion in cancers.
Among them, the expression profiles of MDR1, GAGE1, STAT1 and MAP7 were significantly associated with the expression of
Pyk2 in clinical HCC samples.
Conclusions: Our results may suggest a new evidence of Pyk2 on promoting cisplatin resistance of HCC cells through
preventing cell apoptosis, activation of AKT pathway and upregulation of drug resistant genes.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most fatal
diseases all over the world, particularly in developing countries[1].
Besides surgical treatments, systematic chemotherapy, play crucial
roles in HCC treatment especially for patients with advanced
HCC [2]. However, none of the single drug treatment strategies
such as cisplatin, doxorubicin or 5-FU have shown significant
survival benefit due to a high incidence rate of chemoresis-
tance[2,3]. Several potential molecular pathways in HCC are
targeted for therapeutic interventions such as angiogenesis
pathway, Raf/mitogen-activated protein kinase (MAPK)/extra-
cellular signal-regulated kinase (ERK) pathways, epidermal growth
factor receptor-1 (EGFR) and phospatidylinositol-3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) pathway and
WNT/b-catanin pathway [4,5,6].Among those targeted agents,
sorafenib, an oral multikinase inhibitor blocking tumor cell
proliferation and angiogenesis, is the first agent to demonstrate a
statistically significant improvement in the overall survival of HCC
patients [7,8]. However, most of the targeted agents demonstrated
a very low response rate even for sorafenib [9]. So far, molecular
mechanism of chemoresistance of HCC is not very clear, pushing
an urgent need to seek for novel targets to understand and
overcome this pressing issue.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
key mediator of integrin-mediated signaling pathways that
regulates cellular interactions with extracellular matrix
[10,11,12]. Several lines of evidences suggested that FAK plays
important roles in tumor initiation, progression and metastasis
through manipulation of signaling pathways for survival, prolifer-
ation, migration, epithelial-mesenchymal transition, invasion, and
angiogenesis [10,11,13]. Proline-rich tyrosine kinase (Pyk2) is a
FAK related family member, sharing a 65% similarity in amino
acid sequence and showing similar effect to FAK in regulation of
cell motility and invasion [14,15]. Pyk2 plays important parts in
regulating the proliferation, differential and progression of human
cancers including prostate cancer [16,17,18], lung cancer [19] and
breast cancer [20,21]. We previously found that there is significant
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correlation in the expression of FAK and Pyk2 in HCC patients
[22]. FAK and Pyk2 are overexpressed in nearly 60% of tumor
tissues of HCC patients. Moreover, overexpression of FAK in
HCC patients is significantly correlated with larger tumor size,
advanced new Edmonson’s stage and shorter disease-free survival
while positive overexpression of Pyk2 is significantly correlated
with larger tumor size, advanced new Edmonson’s stage, venous
invasion, shorter overall survival and shorter disease-free survival,
suggesting that Pyk2 is an important prognostic marker in addition
to FAK [22]. Functional studies showed that Pyk2 promotes
proliferation and invasiveness of HCCs through activation of c-Src
and ERK/MAPK signaling pathways [23]. Furthermore, Pyk2
can promote motility of HCC cells through induction of epithelial
to mesenchymal transition[24]. A recent study demonstrated that
combination of sunitinib and a FAK/Pyk2 inhibitor (PF-562,271)
effectively inhibits tumor angiogenesis and aggressiveness of
human hepatoma in a rat xenograft model [25]. Based on the
experimental and clinical evidence of Pyk2 on HCC progression
and invasion, we hypothesize the possibility of Pyk2 on promoting
drug resistance of HCC. In this study, we tried to investigate the
role of Pyk2 in chemoresistance of HCC through a series of in vitro
and in vivo functional studies.
Materials and Methods
Plasmids and antibodies
Plasmids pCDNA3-Pyk2 and pCDNA3-PRNK were gifts from
Dr. Joseph Loftus, Mayo Clinic Scottsdale, USA. pCDNA3.1 (+)
vector was purchased from Invitrogen (Carlsbad, CA). Monoclo-
nal antibody against Pyk2 (clone 11) was purchased from BD
Transduction Laboratories (San Jose, CA). Monoclonal antibody
Phospho-Akt (Ser473) and Phospho-Akt (Thr308) were purchased
from Cell Signaling (Danvers, MA). Rhodamine phalloidin, alexa
fluor 488 goat anti-rabbit immunoglobulin G, alexa fluor 488
rabbit anti-mouse immunoglobulin G and rhodamine goat anti-
rabbit immunoglobulin G antibodies were purchased from
Molecular Probes (Carlsbad, CA).
Chemotherapeutic drug (Cisplatin)
Cisplatin was manufactured in the Netherlands, Haarlem by
Pharmachemie BV. The storage concentration is 1 mg/ml
(50 ml = 50 mg) and kept at room temperature (15,25uC).
HCC patients, specimens and cell lines
Total RNAs were extracted from 43 pairs of HCC specimens
(tumor and adjacent nontumorous liver tissues) collected at the
Department of Surgery, Queen Mary Hospital, Hong Kong,
China SAR. Clinical information was available from these 43
patients. All samples were anonymously coded according to the
local ethical guidelines (as outlined by the Declaration of Helsinki),
and informed written consents were obtained from all patients.
The study was approved by the ethic committee of the University
of Hong Kong.
Human HCC cell lines PLC and Hep3B were purchased from
ATCC (Manassas, VA, USA) and were grown in Dulbecco’s
modified eagle medium containing 10% FBS, 2 mM L-glutamine,
100 units/ml of penicilium and streptomycin (Life Technologies,
Carlsbad, CA). Human metastatic HCC cell line MHCC97L was
a gift from Prof. Z.Y.Tang of Fudan University, Shanghai, China.
Establishment of HCC stable transfectants
Cell transfection and isolation of stable transfectants were
performed following the protocols reported previously[22].
Different protein expression patterns of Pyk2 in HCC cell lines
were demonstrated in the previous study. Pyk2 expression level
was significantly higher in Metastatic cell line MHCC97L by
comparing with PLC and Hep3B. The full length of Pyk2 was
transfected into PLC and Hep3B cell lines to increase the
expression level of Pyk2. Meanwhile, the C-terminal of Pyk2,
which was also called PRNK, was transfected into the MHCC97L
cell line as a dominant negative to knock-down the Pyk2
expression level, whereas pCDNA3.1 (+) was transfected into
these three HCC cell lines as a control.
Western blot
Western blot assay was modified from a previous method [26].
Briefly, whole protein of stable transfectants was extracted using
cell lysis buffer (Cell Signaling Technology, Beverly, MA). After
protein concentration was determined by Bradford protein assay
(BioRad, Hercules, CA), resolved proteins were transferred onto
PVDF membranes (Amersham Biosciences, Piscataway, NJ) using
mini Trans-blot cell (BioRad, Hercules, CA) with 16 transfer
buffer at 4uC overnight. They were then incubated with
corresponding primary antibodies at 4uC overnight. And then
they were incubated with proper secondary antibodies. Finally,
immune reactive signals were visualized by ECL Plus Western
blotting Detection Reagents (GE Healthcare Bucks, UK). The
molecular weights of the positive bands were determined by
comparing their molecular weight with proper protein ladder
(Fermentas, Gern Burnie, MD) on the membranes.
Reverse Transcriptase-PCR
RT-PCR was performed to determine the mRNA level of the
gene. Prior to RT-PCR analysis, contaminated genomic DNA in
the RNA sample was removed by DNase I treatment (Invitrogen).
Each of 1 mg RNA sample was treated with DNase I in a 10-ml
reaction mixture containing 1 ml of DNase I (U/ml) and 1 ml of
10X DNase I buffer at room temperature for 10 minutes. One
microliter of 25 mM EDTA was added followed by incubation at
65uC for 10 minutes. Each cDNA product was synthesized from
1 mg of RNA using the high capacity cDNA kit (Applied
Biosystems, Foster City, CA, USA) under 25uC for 5 minutes
and then 37uC for 2 hours. For cell line samples, PCR reaction for
target genes including Pyk2, MDR1, GAGE, STAT1, Caspase9
and MAP7 was performed by using Taq PCR Kit (Promega,
Madison, WI, USA) under the following PCR cycles: 95uC for 5
minutes, 35 cycles at 95uC for 1 minute, 57uC for 1 minute and
72uC for 1 minute. For internal control 18S, 30 PCR cycles were
used. Primer sets used were described in Table 1.
MTT assay
MTT assay was performed to measure the number of viable
cells under the cisplatin environment. Cells were trypsinized and
counted by using a hemocytometer with 0.2% trypan blue (Life
Technologies). Cells (5,000 cells) were seeded onto 96-well plates
in normal culture condition for overnight. Cells were treated with
different concentrations of cisplatin for 48 hours. MTT was added
into each well and incubated at 37uC for 4 hours. Afterwards,
100 ml of MTT solvent was added into each well to dissolve the
formed crystals. Signals were measured by a plate reader (BioRad).
Each experiment consisted of four replications and at least three
individual experiments were carried out.
Colony formation assay
Colony formation assay was performed to investigate the effects
of Pyk2 overexpression on cell proliferation under cisplatin
environment. Cells (56103 cells/well) were seeded onto 6-well
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plates in normal condition for overnight. The cells were treated
with different concentrations of cisplatin for 2 weeks. Culture
medium was changed twice a week. After 2-week incubation, the
colonies were washed with 16PBS and fixed in 4% paraformal-
dehyde in 16PBS. They were then stained with 0.5% crystal violet
for 25 minutes at room temperature. The colonies were counted
under a light microscope. A mean number of colonies were
obtained from three independent experiments.
Annexin-V-FLOUS assay
Annexin-V-FLOUS assay was applied to measure the percentage
of apoptotic cells under the cisplatin treatment. Firstly, cells were
seeded onto 6-well plates to 50% confluency. The cells were treated
with different concentrations of cisplatin for 48 hours. Afterwards,
thecells were trypsinized,collectedand washed with PBS. The cell
pellet was suspended in 100 ml of Annexin-V-FLOUS and PI labeling
solution (Annexin-V-FLOUS Staining Kit, Roche) and incubated for
10–15 minutes at 15–25uC. The stained cells were analyzed on the
flow cytometer (FACSCalibur from BD, Franklin Lakes, NJ) by the
CELLQuest software. Each experiment was analysed in triplicate
and at least three independent experiments were performed.
cDNA microarray analysis
cDNA microarray was performed following the protocols
reported previously with some modifications[27]. Briefly, total
RNAs of PLC-vector and PLC-Pyk2-8 transfectants were
extracted by using the RNA spin mini kit (GE Healthcare, Bucks,
UK). Genome-wide expression of human genes was examined
with the GeneChip system Human Genome Microarray (Affyme-
trix, Santa Clara, CA). Microarray data were analyzed by
GeneSpring version 7 (Silicon Genetics, Redwood City, CA).
Genes with 2-fold changes in the expression level were selected
and further analyzed with the software PathwayArchitect
(Stratagene Corporation, La Jolla, CA). cDNA microarray data
and the correlation with clinical samples were confirmed by SYBR
Green real-time qRT-PCR. Primer designs are listed in Table 1.
Orthotopic xenograft liver tumor model
The Orthotopic nude mice liver tumor model was established
using MHCC97L-vector and MHCC97L-PRNK cells [28].
Briefly, approximately 16107 cells in 0.2 ml of a culture medium
were injected subcutaneously into the right flank of Balb/c nude
mice (male, 4 weeks old). The mice were observed daily for signs of
tumor development. Once the subcutaneous tumor reached 1 cm
in diameter, it was removed and cut into 1–2-mm cubes, which
were then implanted into the left lobe of another group of nude
mice (4 weeks old). Cisplatin treatment started 2 weeks after the
implantation. Cisplatin (4 mg/kg) was injected intraperitoneally
into the nude mice every 4 days and lasted for 4 weeks. The
volume of liver tumors was determined according to the methods
described by Janik et al.[29]. No less than six mice were performed
for each group. The study had been licensed according to Animal
(Control of Experiments) Ordinance Chapter 340 by the
Department of Health, Hong Kong Special Administrative
Region. (ref.: (08–490) in DH/HA&P/8/2/3 Pt. 7).
Ectopic xenograft tumorigenesis model
Cells (16106/0.2 ml culture medium) were injected subcutane-
ously into the right flank of Balb/c nude mice (male, 4 weeks old).
Once the diameter of the tumor reached 0.5 cm, the nude mice
were treated by intraperitoneal injection of cisplatin (4 mg/kg)
every 4 days for 4 weeks. The tumor size was recorded for 4-day
intervals. After a 4-week treatment, the mice were sacrificed for
tumor sample collection. No less than six mice were performed for
each group. Animal studies had been licensed according to Animal
(Control of Experiments) Ordinance Chapter 340 by the
Department of Health, Hong Kong Special Administrative
Region. (ref.: (08–490) in DH/HA&P/8/2/3 Pt. 7).
Hematoxylin and eosin (H & E) and TUNEL staining
Tumor tissues were collected from both the ectopic xenograft
tumorigenesis model and orthotopic xenograft liver tumor model.
H & E staining was performed to display the nucleus and
cytoplasm of the paraffin and frozen sections. TUNEL assay was
performed to detect the apoptotic nuclei in paraffin sections by
using in situ Cell Death Detection Kit(Roche Applied Science,
Mannheim, Germany). These two assays were performed
following the protocols reported previously [30].
Statistical analyses
The x2 test was performed to compare discrete variables.
Mann-Whitney U- test was used for statistical comparison of
continuous variables. P,0.05 was considered statistically signifi-
cant. Calculations were performed using the SPSS computer
software version 15 (SPSS, Chicago, IL).
Results
Expression patterns of Pyk2 in HCC stable transfectants
We examined the expressions patterns of Pyk2 protein and
mRNA in the stable transfectants (PLC, Hep3B and MHCC97L)
by Western blot and RT-PCR. The expressions of Pyk2 mRNA
and protein were significantly upregulated in Hep3B-Pyk2-11,
PLC-Pyk2-8 and downregulated in MHCC97L-PRNK (Fig. 1A
and 1B). Pyk2 mRNA were upregulated by 35-fold in Hep3B-Pyk2
and 60-fold in PLC-Pyk2 cells compared to Hep3B-vector and
PLC-vector cells respectively (Fig. 1C).
Overexpression of Pyk2 increased cisplatin-resistance of
HCC cells
The result of MTT assay showed that the number of viable cells
in Pyk2 overexpressing stable transfectants (Hep3B-Pyk2 and
PLC-Pyk2) was significantly higher than the control groups
Table 1. Sequence of primer pairs applied in this study.
Gene name Sequences
Pyk2 (C-terminal) Forward: 59 CGGACTGATGACCTGGTGTA 39
Reverse: 59 TTCTTCACCACCACCACGTA 39
Pyk2 (N-terminal) Forward: 59 TGGGGAGGTCTATGAAGGTG 39
Reverse: 59 ACTGCCTCGCTCATGAACTT 39
MDR1 Forward: 59 CAGAGGGGATGGCTAGTGTT 39
Reverse: 59 CGTGGTGGCAAACAATACAG 39
Casp9 Forward: 59 CTAGTTTGCCCACACCCAGT 39
Reverse: 59 ATGCGTCCAGGGTCTCAAC 39
GAGE Forward: 59 CCGAAGCCTGAAGCTGATAG 39
Reverse: 59 TTCACCTCCTCTGGATTTGG 39
MAP7 Forward: 59 CATGGCACAGCGAGCTATAA 39
Reverse: 59 AGCTGGTTGTCTTGCTTTGG 39
STAT1 Forward: 59 TTCAGGAAGACCCAATCCAG 39
Reverse: 59 TGAATATTCCCCGACTGAGC 39
doi:10.1371/journal.pone.0027362.t001
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(Hep3B-vector and PLC-vector) with administration of cisplatin
(* p,0.05) (Fig. 1D).
In addition to the MTT assay, cell proliferation was evaluated
by colony formation assay (Fig. 2A). The colony forming ability of
Hep3B-Pyk2 cells was1.6-fold and 2.4-fold higher than Hep3B
cells at 12 mM (79.662.5% vs 49.262.7%; p=0.001) and 25 mM
(52.964.0% vs 22.563.9%; p=0.001) of Cisplatin (Fig. 2A). The
difference of colony formatting ability reached to 6-fold at the
50 mM of cisplatin concentration (30.666.2% vs 5.262.1%;
p=0.001). The IC50 of cisplatin to Hep3B-Pyk2 transfectants
was determined as 25 mM which was 2-fold higher than the
Hep3B-vector transfectant (Fig. 2B).
In PLC cells, The colony forming ability of PLC-Pyk2 cells
was1.4-fold and 1.6-fold higher than PLC cells at 6 mM
(69.965.4% vs 50.865.5%; p=0.013) and 8 mM (48.266.0% vs
17.863.7%; p=0.002) of Cisplatin (Fig. 2A). The difference of
colony formatting ability reached to 10-fold at the 10 mM of
cisplatin concentration (18.663.5% vs 1.860.8%; p=0.001). The
Figure 1. The establishment of Pyk2 overexpressed and suppressed stable transfectants. (A), Western blot analysis verified the protein
expression level of Pyk2 in different stable transfectants (PLC, Hep3B and MHCC97L). Significantly higher Pyk2 expression was observed in PLC-Pyk2-8
and Hep3B-Pyk2-11. Pyk2 expression level was knocked down in MHCC97L by transfecting C-terminal of Pyk2. (B), RT-PCR demonstrated Pyk2
expression level in different stable transfectants at mRNA level. (C), Real time RT-PCR quantified Pyk2 expression level in these stable transfectants.
(D), MTT assay showed that overexpression of Pyk2 promoted HCC cell proliferation rates upon increasing concentrations of cisplatin treatment.
doi:10.1371/journal.pone.0027362.g001
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IC50 of cisplatin to PLC-Pyk2 transfectants was determined as
6.3 mM which was 1.5-fold higher than the PLC-vector transfec-
tant (Fig. 2B).
In MHCC97L cell lines with overexpressed Pyk2, transfection
of PRNK significantly down-regulated its colony forming ability.
There was a 2.7-fold, 2.5 fold and 4-fold decrease of colony
forming ability as compared to the transfectants with empty vector
at 9 mM (76.964.4 vs 28.862.2%; p=0.001), 12 mM of cisplatin
concentration (50.262.7 vs 19.862.1%; p=0.001) and 25 mM of
cisplatin concentration (36.964.4 vs 19.862.7%; p=0.001). The
IC50 of cisplatin to MHCC97L-PRNK transfectants was 5.5 mM
which was 1.8-fold lower than the MHCC97L-vector transfectants
(Fig. 2B). The cell viability (%) of each cell line under different
concentrations of cisplatin was determined by colony formation
assay and the results were presented in means6SD calculated
from three independent experiments.
Overexpression of Pyk2 reduced apoptosis of HCC cell
lines upon cisplatin treatment
The effect of Pyk2 overexpression on cell apoptosis under the
cisplatin environment was analyzed by propidium iodide and
Annexin-V staining following by FACS analysis. The result
demonstrated that PLC-Pyk2 exhibited a lower rate of apoptosis
upon cisplatin environment than PLC-vector cells (Fig. 2C). When
the concentration of cisplatin rose up to 9 mM, 12 mM and 15 mM,
the percentage of apoptotic cell in PLC-vector was more than 2-
fold of the PLC-Pyk2 cells (9 mM: 33.863.7% vs 11.061.5%,
12 mM: 42.364.8% vs 18.262.2%, p=0.017; 15 mM: 45.965.1%
vs 19.862.7%, p,0.01, Fig. 2D).
Suppression of Pyk2 increased tumor necrosis/apoptosis
upon cisplatin treatment
We employed an ectopic xenograft model by subcutaneous
injection of MHCC97L-vector and MHCC97L-PRNK cells into
the nude mice. The result showed that the MHCC97L-PRNK
group displayed a significantly reduced size of subcutaneous tumor
compared to the MHCC97L-vector group after 6 times of cisplatin
treatment (199.9610.8 mm3 vs 138.9614.6 mm3; p=0.006,
Fig. 3A). The growth rate of tumor in MHCC97L-PRNK was
significantly slower than that in the MHCC97L-vector group
(* p,0.05) (Fig. 3B). By measuring the percentage of necrosis at 5
different fields from 3 mice, higher percentage of necrotic cells was
observed in the MHCC97L-PRNK group compared with
MHCC97L-vector group (57.365.4% vs 32.864.9%, p=0.037;
Figure 2. The effects of Pyk2 overexpression on HCC cell proliferation and apoptosis upon cisplatin treatment. (A), Colony Formation
assay demonstrated that Pyk2 overexpressed stable transfectants had significantly higher cell proliferation rate upon increasing concentrations of
cisplatin treatment. (B), Comparison of colony forming abilities among the HCC cell lines. * p,0.05; ** p,0.01. (C), Annexin-V-FLOUS assay showed
that Pyk2 overexpression in PLC led to a reduction of apoptosis upon cisplatin treatment. (FL1 =Annexin-V-FLUOS, FL2 =prodium iodide; R1 = Living
cells, R2 = apoptotic cells, R3 =necrotic cells) (D), Annexin-V-FLOUS assay showed that the percentage of apoptotic cells was significantly lower in
PLC-Pyk2 by comparing with PLC-vector upon different concentrations of cisplatin treatment. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0027362.g002
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Figure 3. The establishment of subcutaneous xenograft nude mice model. (A), Liver tumor growth after cisplatin treatment. (B), Comparison
of liver tumor growth * p,0.05 (C), H&E staining showed that tumor necrosis was more severe in MHCC97L-PRNK generated tumor (magnification
640). By measuring the percentage of necrotic tumor at 5 different fields from 3 mice, more significant necrosis was observed in the MHCC97L-PRNK
group. (D), TUNEL staining showed that tumor cell apoptosis was more severe in MHCC97L-PRNK generated tumor (magnification640). By counting
the number of apoptotic particles at 5 different fields from 3 mice, more apoptotic cells were observed in MHCC97L-PRNK group.
doi:10.1371/journal.pone.0027362.g003
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Fig. 3C). By counting the number of apoptotic cells at 5 different
fields from 3 mice, more apoptotic cells were observed in
MHCC97L-PRNK group compared to the MHCC97L-vector
group (53.766.9 vs 26.963.1, p=0.021; Fig. 3D).
In the orthotopic xenograft model, tumor size in MHCC97L-
PRNK was significantly reduced compared to the MHCC97L-
vector group (MHCC97L-vector: 301.7616.7 mm3; MHCC97L-
PRNK: 120.6610.3 mm3, p=0.023, Fig. 4A). By measuring the
percentage of necrotic tumor cells at 5 different fields from 3 mice,
higher percentage of necrotic cells was observed in the MHCC97L-
PRNK group compared to the MHCC97L-vector group
(73.164.4% vs 31.364.3%, p=0.016; Fig. 4B). Moreover, more
apoptotic cells were observed in MHCC97L-PRNK group than the
MHCC97L-vector group (62.365.1 vs 34.966.0%, p=0.031;
Fig. 4C). The expression level of Pyk2 mRNA in tumor tissues was
further confirmed by RT-PCR to be downregulated in MHCC97L-
PRNK group in both ectopic and orthotopic xenograft models
(Fig. 4D). Moreover, phosphorylated Akt was also demonstrated to
be overexpressed in MHCC97L-vector generated tumor in
subcutaneous nude mice model and orthotopic model by western
blot (Fig. 4E).These results indicated that Pyk2 overexpression had a
significant effect on tumor growth by activation of pAkt, as well as
inhibition of tumor necrosis and apoptosis upon cisplatin treatment.
Overexpression of Pyk2 differentially regulated multidrug
resistant genes in HCC cells
The mechanisms of Pyk2 overexpression related cisplatin
resistance in HCC were investigated by cDNA microarray analysis.
After comparing the gene profiles of PLC-Pyk2-8 and PLC-vector
cells, 4,322 upregulated and 1,891 downregulated genes were found
in PLC-Pyk2-8 cells. The functions of most upregulated genes were
identified to be involved in signal transduction (16%), transcription
(14%), cell defense response (8%), immune response (8%), cell cycle
(8%), cell proliferation (8%), cell adhesion (6%), apoptosis (6%), and
cell growth (4%). Among those downregulated genes, most
functions were related to nucleic acid binding (29%), transcription
factor activity (17%), protein binding (15%), apoptosis (10%), signal
transducer activity (5%), negative regulation of cell proliferation
(5%), and cell cycle (5%) (Fig. S1). Fifty-five upregulated genes and
50 downregulated genes with more than 2-fold changes were
identified (Table S1). These target genes were narrowed down by
their correlation with cisplatin resistance and HCC invasiveness
subsequently. G antigen 1 (GAGE1), multidrug resistant gene-1
(MDR1), signal transducer and activator of transcription (STAT1),
Caspase9 and microtubule-associated protein 7 (MAP7) were
chosen for further validation by RT-PCR. Most of them could
also be verified to be differentially expressed in Hep3B and
MHCC97L cell lines (Fig. 5A).
To examine the expression correlation between Pyk2 and these
genes in HCC patients, the expression profiles of MDR1, GAGE1,
Caspase9, MAP7 and STAT1 mRNA in 43 pairs of tumor and
adjacent non-tumor liver tissues of HCC patients underwent
hepatectomy were analyzed. Pyk2, MDR1, GAGE1, MAP7 and
STAT1 were found to be overexpressed in more than 60% of the
tumor liver tissues compared to the adjacent non-tumor liver
tissues (*p,0.05) (Table 2 and Fig. 5B). The expressions patterns
of MDR1, GAGE1, MAP7 and STAT1 were significantly
correlated with Pyk2 expression in HCC patients (p,0.01).
Overexpression of Pyk2 activated Akt phosphorylation
upon cisplatin treatment
Western blot analysis was employed to investigate the role of
Pyk2 on AKT signaling pathway of HCC cells in responding to
cisplatin treatment. Akt phosphorylation was activated by cisplatin
in a dose-dependent manner in the HCC cell lines with Pyk2 over-
expression (MHCC97L-vector, PLC-Pyk2 and Hep3B-Pyk2).
While in control groups (MHCC97L-PRNK, PLC-vector and
Hep3B-vector), Phospho-AKT was slightly increased in different
concentrations of cisplatin (Fig. 5C).
Discussion
Although cisplatin is a common therapeutic agent used for
chemotherapy in HCC patients, its curative effect is significantly
limited due to chemoresistance of HCC [31]. Acquisition of
cisplatin resistance during chemotherapy becomes a vital factor to
cancer mortality and remains a major clinical obstacle. Cisplatin
is a cytotoxic compound that causes apoptosis via DNA damage
by formation of interstrand or intrastrand adducts[32]. The
cytotoxic effect of cisplatin is a complex process that leads to
activation of several pathways organized in a large network.
Blockade of any of the signaling involved may result in reduction
of chemosensitivity. In general, mechanisms inhibiting propaga-
tion of the DNA damage signal to the apoptosis include loss of
damage recognition, overexpression of HER-2/neu, activation of
the PI3-K/AKT pathway, loss of p53 function, overexpression of
anti-apoptotic bcl-2, and interference in caspase activation [33].
Upon disregulations of these genes, cisplatin resistance could be
induced by several aspects including reduction of intracellular
drug accumulation, increased inactivation by the thiol-containing
molecules, increasing of DNA damage repair and inhibition of
apoptosis. However, the mechanisms of cisplatin resistance in
HCC and the mechanism underlying clinical cisplatin resistance
remain poorly understood. By fully understanding these mech-
anisms, we may offer a promising approach to mediate cisplatin
sensitivity and the possibility of developing a personalized
therapeutic strategy.
In most studies of chemoresistance, tumor cells with chemore-
sistance were selected by stepwise exposure to increasing
concentrations of chemotherapeutic drugs[34]. After comparing
the difference of gene expression profiles between resistant and
normal cells, several potential target genes were selected for
further study. Therefore the gene overexpressed in a well-
established resistant cell line might be a consequence of the
acquired resistance rather than the direct cause leading to
chemoresistance. In this study, Pyk2-overexpressed stable trans-
fectants were established instead. Afterwards, Pyk2 overexpres-
sion-induced cisplatin resistance was observed in both the in vitro
and in vivo studies. cDNA microarray was performed to explore the
mechanism of Pyk2 overexpression-induced cisplatin resistance
subsequently. The novelty of this approach may allow it to have
the advantage in identifying the direct role of Pyk2 in cisplatin
resistance in HCC.
Pyk2 inherits 60% from the central kinase domain of FAK and
has a similar domain structure with 40% identities in the FAT
domain regions[14]. FAK was also confirmed to be a key factor
involved in liver tumor progression and have prognostic
significance for HCC[35]. We have demonstrated that overex-
pression of Pyk2 can induce the upregulation of c-Src and
ERK[23]. Interestingly, the FAT domain also contains Tyr881,
which serves as a binding site for the adaptor Grb2 and linkage to
the MAP kinase signaling pathway when phosphorylated by Src
[36]. It happens to be a key event to activate PI3-K/AKT
signaling pathway and induce cisplatin resistance subsequent-
ly.[37,38] Based on such information, we hypothesized that
overexpression of Pyk2 may play a crucial part in cisplatin
resistance in HCC.
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Figure 4. The establishment of orthotopic nude mice model. (A), After the cisplatin treatment, the tumor which generated by MHCC97L-
vector is significantly larger than MHCC97L-PRNK group. (B), H&E staining showed that more significant necrosis was observed in the MHCC97L-PRNK
group by measuring the percentage of necrosis at five different fields from 3 mice. * p,0.05. (C), TUNEL staining showed that tumor cell apoptosis
was more severe in MHCC97L-PRNK generated tumor (magnification640) by measuring the percentage of apoptosis at five different fields from 3
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Our results demonstrated that overexpression of Pyk2 could
contribute cisplatin resistance to HCC cells by promoting
proliferation and reducing apoptosis. Moreover, suppression of
Pyk2 by PRNK in MHCC97L cells could reduce cisplatin
resistance of the cells by significantly suppressing its proliferation.
Furthermore, suppression of Pyk2 by PRNK significantly inhibited
mice. * p,0.05 (D), Real time RT-PCR illustrated that Pyk2 was overexpressed in MHCC97L-vector generated tumor in subcutaneous nude mice model
and orthotopic model. * p,0.05. (E), phosphorylated Akt was also demonstrated to be overexpressed in MHCC97L-vector generated tumor in
subcutaneous nude mice model and orthotopic model by western blot.
doi:10.1371/journal.pone.0027362.g004
Figure 5. Exploration of down-regulate signaling pathway and the underlying mechanism. (A), RT-PCR verified that MDR1, GAGE1, MAP7,
and STAT1 have positive correlations the expression level of Pyk2 in PLC, Hep3B and MHCC97L cell lines. (B), Expression level of Pyk2, MDR1, GAGE1,
MAP7, and STAT1 was higher in HCC samples. (C), Dose-dependent western bolt assay demonstrated that Phosph-AKT expression increasing by
following the increasing concentrations of cisplatin treatment in Pyk2 overexpressed stable transfectants (MHCC97L-vector, PLC-Pyk2, Hep3B-Pyk2).
doi:10.1371/journal.pone.0027362.g005
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the orthotopic tumor growth after cisplatin treatment compared to
the control group by induction of tumor cell necrosis and
apoptosis. The above data suggested that overexpression of Pyk2
may be one of the mechanisms contributing to drug resistance in
HCC.
There were more than 6,000 differential genes detected in Pyk2
overexpressing HCC cells and those differential genes were found
to be involved in different biological functions, indicating that
common upregulation of Pyk2 in HCC may contribute to
deregulation of a large number of genes.
The expressions of several drug-resistant genes including
MDR1, GAGE, STAT1, and MAP7 were found to be
overexpressed in three Pyk2 overexpressing HCC cell lines and
in tumor liver tissues of HCC patients. Moreover, their expression
levels also showed significant positive correlations with Pyk2
expression in HCC patients, indicating that upregulations of drug
resistant genes may be a possible mechanism of Pyk2-induced drug
resistance in HCC.
The GAGE1 cDNA contains a 143-bp insertion located in the
coding sequence near the termination codon, which is absent from
the other cDNAs. Interestingly, its expression could be detected in
many types of tumor tissues. However, GAGE expression could be
observed in none of the non-tumor tissues except for testis[39]. A
recent study pointed out that GAGE family members are
expressed in medulloblastoma cells and specimens, and the
inhibition of GAGE genes in MB cells can sensitize them to
certain chemotherapeutic agents such as cisplatin[40]. The MDR1
encodes P-glycoprotein (P-gp) and plays an important role in
mediating multidrug resistance to chemotherapeutic agents. In
cancer, P-gp overexpression is associated with a poor response to
chemotherapy[41]. Overexpression of MDR1 was observed in
many types of cancer such as HCC[42] and non-small-cell lung
cancer[43]. In HCC, it was proven that amplification of MDR1
mRNA is probably the main mechanism underlying acquired
doxorubicin resistance[44]. The protein encoded by STAT1 is a
member of the STAT protein family. In HCC cell lines,
knockdown of STAT1 or Janus kinase1 suppressed the dephos-
phorylation of both ERK and MEK and diminished the cell
growth[45]. Therefore, upregulation of STAT1 may promote cell
proliferation even under the cisplatin environment. Additionally,
STAT1 belongs to the IFN-related DNA damage resistance
signature which is proven to be associated with resistance to
chemotherapy across different cancer cell lines[46]. The product
of MAP7 is a microtubule-associated protein predominantly
expressed in cells of an epithelial origin. Microtubule-associated
proteins are thought to be involved in microtubule dynamics,
which is essential for cell polarization and differentiation. Some
studies indicated that determination of mRNA levels of MAP7
may be useful for prediction of the success of neoadjuvant
chemotherapy in Barrett’s carcinoma[47]. Since these drug-
resistance related genes were up-regulated by Pyk2, it may
suggested that Pyk2 overexpression could be a crucial factor in
cisplatin resistance in HCC. To further study the underlying
mechanism of Pyk2 induced cisplatin resistance, we need to find
out which pathways were activated by overexpression of Pyk2 in
HCC.
Many studies suggested PI3K/AKT/mTOR survival pathway
plays an important role in cisplatin resistance in ovarian
cancer[48], lung cancer[49] and breast cancer[50]. Moreover,
the inhibitor of AKT was proven to have significant effect on
increasing cisplatin sensitivity in these cancers. Therefore, AKT
was considered to be a potential target to overcome cisplatin
resistance. In HCC, PI3K/AKT pathway was also demonstrated
to have significant correlations with cisplatin resistance[37]. The
blockade of Akt/HIF-1alpha/PDGF-BB autocrine signaling can
enhance the chemosensitivity of liver cancer cells and tumorigenic
hepatic progenitor cells under hypoxic conditions[38]. Based on
these information, we hypothesized Pyk2 may induce cisplatin
resistance in HCC by activation of PI3K/AKT pathway. To
confirm our hypothesis, a dosage-dependent assay was preformed
to demonstrate the correlation between Pyk2 and AKT activation.
The result showed that phosphorylated AKT expression level was
gradually increased by increased concentrations of cisplatin in
Pyk2 overexpressed HCC cell lines (MHCC97L-vector, PLC-Pyk2
and Hep3B-Pyk2). However, this dose-dependent response could
not be observed in HCC cells with lower Pyk2 expression
(MHCC97L-PRNK, PLC-vector and Hep3B-vector) (Fig. 5C).
This result indicated that when HCC cell line was treated with
cisplatin, overexpression of Pyk2 could induce the upregulation of
AKT in a cisplatin dose-dependent manner. Moreover, the
activation of pAkt was also well correlated with higher expression
of Pyk2 and less tumor apoptosis in our in vivo models underwent
cisplatin treatment.
In summary, our results showed that overexpression of Pyk2 is
associated with acquired cisplatin resistance in HCC through
promoting cell proliferation, reducing apoptosis, activation of
AKT pathways and upregulation of drug-resistant genes. Pyk2
may not only be applied as a potential predictive marker of
chemoresistance for platinum-based chemotherapy in HCC
patients, but also be a novel therapeutic target in HCC.
Supporting Information
Figure S1 Gene profiles of two stable transfectants were
compared between PLC-Pyk2–8 and PLC-vector.
(TIFF)
Table S1 Gene profiles regulated by Pyk2.
(DOC)
Table 2. Expression level of Pyk2, MDR1, GAGE, MAP7 and STAT1 in 43 pairs of clinical samples.
Gene name Suppression Over-expression Highly over-expression* No difference
Pyk2 11.6%(5/43) 65.1%(28/43) 46.5%(20/43) 23.2%(10/43)
MDR1 9.3%(4/43) 60.5%(26/43) 41.8%(18/43) 30.2%(13/43)
Casp9 30.2%(13/43) 46.6%(20/43) 44.2%(19/43) 23.2%(10/43)
GAGE 13.9%(6/43) 79.1% (34/43) 65.1%(28/43) 7.0%(3/43)
MAP7 18.6%(8/43) 62.8% (27/43) 44.2%(19/43) 18.6%(8/43)
STAT1 27.9%(12/43) 65.1%(28/43) 46.5%(20/43) 7.0%(3/43)
*More than 2 fold difference in the tumor tissue.
doi:10.1371/journal.pone.0027362.t002
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